NASDAQ:MGNX MacroGenics - MGNX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.77 +0.15 (+2.67%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$5.58▼$5.8650-Day Range$5.17▼$6.9252-Week Range$2.13▼$12.79Volume559,843 shsAverage Volume541,457 shsMarket Capitalization$354.68 millionP/E RatioN/ADividend YieldN/APrice Target$9.56 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability MacroGenics MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside65.6% Upside$9.56 Price TargetShort InterestBearish7.38% of Float Sold ShortDividend StrengthN/ASustainability-1.61Upright™ Environmental ScoreNews Sentiment0.54Based on 2 Articles This WeekInsider TradingAcquiring Shares$4.88 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.48) to ($2.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector222nd out of 1,055 stocksPharmaceutical Preparations Industry107th out of 518 stocks 4.3 Analyst's Opinion Consensus RatingMacroGenics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.56, MacroGenics has a forecasted upside of 65.6% from its current price of $5.77.Amount of Analyst CoverageMacroGenics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.38% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in MacroGenics has recently increased by 5.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for MacroGenics is -1.61. Previous Next 2.5 News and Social Media Coverage News SentimentMacroGenics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MacroGenics this week, compared to 3 articles on an average week.Search Interest6 people have searched for MGNX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,881,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of MacroGenics is held by insiders.Percentage Held by Institutions93.63% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MacroGenics are expected to decrease in the coming year, from ($1.48) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MacroGenics (NASDAQ:MGNX) StockMacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.Read More Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGNX Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comTarget N. V. Biotech Purchases 150,000 Shares of MacroGenics, Inc. (NASDAQ:MGNX) StockJanuary 6, 2023 | finance.yahoo.comMacroGenics (MGNX) Stock Sinks As Market Gains: What You Should KnowFebruary 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 4, 2023 | finance.yahoo.comMacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of DirectorsJanuary 4, 2023 | finance.yahoo.comMacroGenics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2023 | finance.yahoo.comInvestors in MacroGenics (NASDAQ:MGNX) from five years ago are still down 66%, even after 13% gain this past weekDecember 6, 2022 | finance.yahoo.comMacroGenics, Inc. (NASDAQ:MGNX) insider upped their holding by 26% earlier this yearDecember 5, 2022 | finance.yahoo.comCan MacroGenics (MGNX) Climb 74% to Reach the Level Wall Street Analysts Expect?February 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 2, 2022 | finance.yahoo.comMacroGenics (MGNX) Recently Broke Out Above the 20-Day Moving AverageNovember 22, 2022 | finance.yahoo.comWhy Shares of MacroGenics Were Dropping TuesdayNovember 18, 2022 | finance.yahoo.comRockville’s MacroGenics scores $60M from Provention Bio’s FDA approvalNovember 17, 2022 | finance.yahoo.comWall Street Analysts Believe MacroGenics (MGNX) Could Rally 123%: Here's is How to TradeNovember 15, 2022 | finance.yahoo.comWhy MacroGenics Stock Crushed the Market on MondayNovember 9, 2022 | finance.yahoo.comMacroGenics Third Quarter 2022 Earnings: Beats ExpectationsNovember 4, 2022 | finance.yahoo.comMacroGenics (MGNX) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comMacroGenics Provides Corporate Update and Third Quarter 2022 Financial ResultsNovember 1, 2022 | finance.yahoo.comWall Street Analysts See a 279% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?October 26, 2022 | finance.yahoo.comMacroGenics Announces Date of Third Quarter 2022 Financial Results Conference CallOctober 25, 2022 | finance.yahoo.comMacroGenics (MGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?October 25, 2022 | finance.yahoo.comIndustry Analysts Just Upgraded Their MacroGenics, Inc. (NASDAQ:MGNX) Revenue Forecasts By 10%October 21, 2022 | nasdaq.comStrong week for MacroGenics (NASDAQ:MGNX) shareholders doesn't alleviate pain of one-year lossOctober 19, 2022 | finance.yahoo.comTransCode Therapeutics: Invitation to The ThinkEquity Conference - Yahoo FinanceOctober 18, 2022 | finance.yahoo.comRoche exec says Biogen Alzheimer's data was reassuring - Yahoo FinanceOctober 18, 2022 | nasdaq.comGilead's (GILD) Yescarta Gets EC Nod for New Cancer Indication - NasdaqOctober 17, 2022 | finance.yahoo.comMilestone Pharma Stock Surges After Successful Trial For Abnormal Heart Rhythm Candidate - Yahoo FinanceOctober 17, 2022 | finance.yahoo.comMinerva Neurosciences Shares Sink On Regulatory Setback For Schizophrenia Candidate - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGNX Company Calendar Last Earnings11/03/2022Today1/31/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGNX CUSIPN/A CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees427Year Founded2000Price Target and Rating Average Stock Price Forecast$9.56 High Stock Price Forecast$16.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+65.6%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-202,120,000.00 Net Margins-204.95% Pretax Margin-204.95% Return on Equity-111.57% Return on Assets-74.73% Debt Debt-to-Equity RatioN/A Current Ratio2.95 Quick Ratio2.93 Sales & Book Value Annual Sales$77.45 million Price / Sales4.58 Cash FlowN/A Price / Cash FlowN/A Book Value$3.91 per share Price / Book1.48Miscellaneous Outstanding Shares61,470,000Free Float56,618,000Market Cap$354.68 million OptionableOptionable Beta2.04 Social Links Key ExecutivesScott E. KoenigPresident, Chief Executive Officer & DirectorEric RisserChief Operating OfficerJames KarrelsChief Financial Officer, Secretary & Senior VPEzio BonviniChief Scientific Officer & Senior VP-ResearchStephen L. EckChief Medical Officer & SVP-Clinical DevelopmentKey CompetitorsPMV PharmaceuticalsNASDAQ:PMVPStoke TherapeuticsNASDAQ:STOKALX OncologyNASDAQ:ALXOAtea PharmaceuticalsNASDAQ:AVIRAdicet BioNASDAQ:ACETView All CompetitorsInsiders & InstitutionsNew York State Common Retirement FundBought 8,112 shares on 1/30/2023Ownership: 0.058%Pinnacle Associates Ltd.Sold 50,020 shares on 1/25/2023Ownership: 0.598%Allspring Global Investments Holdings LLCBought 6,451 shares on 1/23/2023Ownership: 0.015%Target N V BiotechBought 150,000 shares on 1/19/2023Total: $795,000.00 ($5.30/share)Assenagon Asset Management S.A.Sold 305,746 shares on 1/12/2023Ownership: 2.428%View All Insider TransactionsView All Institutional Transactions MGNX Stock - Frequently Asked Questions Should I buy or sell MacroGenics stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares. View MGNX analyst ratings or view top-rated stocks. What is MacroGenics' stock price forecast for 2023? 10 analysts have issued 12 month price targets for MacroGenics' shares. Their MGNX share price forecasts range from $5.00 to $16.00. On average, they anticipate the company's share price to reach $9.56 in the next year. This suggests a possible upside of 68.8% from the stock's current price. View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts. How have MGNX shares performed in 2023? MacroGenics' stock was trading at $6.71 at the beginning of 2023. Since then, MGNX shares have decreased by 15.6% and is now trading at $5.66. View the best growth stocks for 2023 here. When is MacroGenics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our MGNX earnings forecast. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) announced its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.09. The biopharmaceutical company had revenue of $41.73 million for the quarter, compared to the consensus estimate of $22.74 million. MacroGenics had a negative trailing twelve-month return on equity of 111.57% and a negative net margin of 204.95%. What is Scott Koenig's approval rating as MacroGenics' CEO? 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC). What is MacroGenics' stock symbol? MacroGenics trades on the NASDAQ under the ticker symbol "MGNX." Who are MacroGenics' major shareholders? MacroGenics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (2.43%), Pinnacle Associates Ltd. (0.60%), Hennion & Walsh Asset Management Inc. (0.06%), New York State Common Retirement Fund (0.06%), Allspring Global Investments Holdings LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel. View institutional ownership trends. How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MacroGenics' stock price today? One share of MGNX stock can currently be purchased for approximately $5.66. How much money does MacroGenics make? MacroGenics (NASDAQ:MGNX) has a market capitalization of $347.92 million and generates $77.45 million in revenue each year. The biopharmaceutical company earns $-202,120,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis. How many employees does MacroGenics have? The company employs 427 workers across the globe. How can I contact MacroGenics? MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for the company is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321. This page (NASDAQ:MGNX) was last updated on 2/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.